Form 4: ANI Pharmaceuticals Executive Sells 400 Shares Under 10b5-1 Trading Plan

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 400 shares of common stock at $68.96 per share on April 14, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On April 14, 2025, Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 400 shares of common stock.
• The shares were sold at a price of $68.96 per share.
• Following the transaction, Cook directly owns 80,145 shares of ANI Pharmaceuticals.
• The sale was executed under a Rule 10b5-1 trading plan adopted on September 17, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company.

Industry Context

Insider transactions are routinely monitored by investors as they can provide signals, though sales under 10b5-1 plans are less informative due to their pre-arranged nature.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

ANI Pharmaceuticals, Meredith Cook, Form 4, insider trading, stock sale, Rule 10b5-1, ANIP, executive compensation